Exposure Analysis

Exposure analysis quantifies your organization's current and projected GLP-1 pharmacy spend trajectory. This is not predictive modeling. This is conservative financial analysis grounded in clinical assumptions.

What we measure

We measure current GLP-1 spend, adherence rates, member eligibility trends, and formulary positioning. We project future spend using conservative assumptions about uptake velocity and long-term persistence.

How projections are structured

Projections include baseline scenarios (no intervention), managed tapering scenarios (with clinical protocols), and confidence intervals. We do not provide optimistic projections. All assumptions are documented and available for institutional review.

Outputs

Analysis outputs include executive summary reports, detailed cost trajectories, cohort segmentation, and risk-adjusted savings estimates. Reports are designed for CFO and benefits committee consumption.

When to request an analysis

Request an exposure analysis if your GLP-1 spend has increased significantly year-over-year, if you are uncertain about long-term cost trajectories, or if you are evaluating managed containment options.